Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naive patients with extensive-disease small cell lung cancer

Cancer

Volumn 116, Issue 1, 2010, Pages 132-136

  Lee, Dae Ho ^a   Kim, Sang We ^a   Suh, Cheolwon ^a   Lee, Jung Shin ^a   Ahn, Jin Seok ^b   Ahn, Myung Ju ^b   Park, Keunchil ^b   Na, Im Il ^c   Lee, Jae Cheol ^c   Ryoo, Baek Yeol ^c   Yang, Sung Hyun ^c  

^a University of Ulsan College of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Korea Cancer Center Hospital   (South Korea)

Author keywords

Belotecan; Chemotherapy naive; Cisplatin; Extensive stage disease; Small cell lung cancer

Indexed keywords

BELOTECAN; CISPLATIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONSTIPATION; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; EXTENSIVE DISEASE SMALL CELL LUNG CANCER; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; HYPOALBUMINEMIA; HYPONATREMIA; LEUKOPENIA; LUNG SMALL CELL CANCER; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NATIONAL HEALTH ORGANIZATION; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT REFUSAL; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; SMALL CELL LUNG CARCINOMA;

EID: 74549210554     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24719     Document Type: Article

References (10)

1. Lee JH, Lee JM, Kim JK, et al. Antitumor activity of 7-[2(N- isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor. Arch Pharm Res. 1998;21:581-590.
2. Lee JH, Lee JM, Lim KH, et al. Preclinical and phase I clinical studies with CKD-602, a novel camptothecin derivative. Ann N Y Acad Sci. 2000;922:324-325.
3. Lee DH, Kim SW, Suh C, et al. Belotecan, new camptothecin analogue, is active in patients with small cell lung cancer: results of a multicenter early phase II study. Ann Oncol. 2008;19:123-127.
4. Lee DH, Kim SW, Bae KS, et al. A phase I and pharmacological study of belotecan in combination with cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. Clin Cancer Res. 2007;13:6182-6186.
5. Chang MN, Therneau TM, Wieand HS, et al. Designs for group sequential phase II clinical trials. Biometrics. 1987;43:863-874.
6. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346:85-91.
7. Hanna NH, Bunn PA, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006; 24:2038-2043.
8. Eckardt JR, Pawel J, Papai Z, et al. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer. J Clin Oncol. 2006;24:2044-2051.
9. Natale RB, Lara PN, Chansky K, et al. S0124: a randomized phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients with previously untreated extensive stage small cell lung cancer (E-SCLC) [abstract]. J Clin Oncol. 2008;26S. Abstract 7512.
10. Heigener DF, Freitag L, Eschbach R, et al. Topotecan/cisplatin (TP) compared to cisplatin/etoposide (PE) for patients with extensive disease-small cell lung cancer (EDSCLC): final results of a randomised phase III trial [abstract]. J Clin Oncol. 2008;26S. Abstract 7513.